tranScrip
Trisha Byrne has extensive work experience in regulatory affairs within the medical technology industry. Trisha is currently an Associate Director of Regulatory Affairs at tranScrip since April 2023. Prior to this, they worked at Real Regulatory Ltd as a Regulatory Affairs Manager for Medical Technology from November 2022 to April 2023, and as a Senior Regulatory Affairs Consultant from August 2021 to November 2022. Trisha also held the position of International Regulatory Affairs Manager at DeRoyal from October 2013 to August 2021. Before that, they worked at Allergan as a Regulatory Affairs Manager for Medical Devices from January 2013 to September 2013, and as a Senior Regulatory Affairs Analyst for Medical Devices from May 2009 to January 2013. Trisha's earlier experience includes working as a Regulatory Affairs Project Co-ordinator at Allergan from May 2008 to February 2009, and as a Research Scientist at Vasogen Inc from November 2003 to May 2008.
Trisha Byrne obtained a BSc (Hons) degree in Science from Maynooth University in 1999. Trisha then pursued a PhD in Immunology at Trinity College Dublin from 1999 to 2003. In 2021, Trisha completed a Professional Diploma in Project Management from UCD Professional Academy.
This person is not in any offices
tranScrip
tranScrip is a leading contract drug development organisation which supports pharma and biotech companies in the development and lifecycle of medicines. We bring innovative solutions to clients’ global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements. Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches. In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.